Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
25.0%
招募中
3
75.0%
暂无批准数据
- Perspective Therapeutics and Merck signed a clinical trial collaboration and supply agreement to evaluate [212Pb]PSV359 with Keytruda (pembrolizumab) in FAP-α-positive solid tumors. - The combination will be studied under an amendment to Perspective's ongoing Phase 1/2a trial (NCT06710756) in non-small cell lung cancer and colorectal cancer, with the first three monotherapy dose cohorts fully enrolled. - Perspective is sponsoring the study and Merck is supplying pembrolizumab at no cost, with the collaboration aiming to reshape the immunosuppressive tumor microenvironment. - FAP-α is expressed on cancer-associated fibroblasts in most epithelial cancers and is linked to poor prognosis across multiple solid tumor types including NSCLC and colorectal cancer.
- Novartis executives project the radioligand therapy market could reach at least $10 billion for the company alone, with industry leaders expecting tens of billions in total market value. - Theranostic radiopharmaceuticals, which combine diagnostic imaging with targeted radiation therapy, are emerging as "the future" of the field by enabling precise patient selection and treatment monitoring. - Major pharmaceutical companies including Bristol Myers Squibb, Eli Lilly, and AstraZeneca have invested billions in radiopharmaceutical acquisitions, with venture financing reaching a record $408 million in 2023. - Industry experts identify supply chain bottlenecks, imaging capacity constraints, and specialized manufacturing requirements as key challenges that must be addressed before widespread market expansion.
- Perspective Therapeutics appointed biotech veteran Joel Sendek as Chief Financial Officer, bringing extensive experience from four previous CFO roles and over $2.5 billion in fundraising expertise. - Sendek joins as the radiopharmaceutical company advances three clinical programs using proprietary 212Pb alpha-emitting isotope technology for targeted cancer treatment. - The appointment comes during ongoing Phase 1/2a trials for neuroendocrine tumors, melanoma, and solid tumors, positioning the company to establish leadership in targeted alpha radiopharmaceutical therapy.
- Perspective Therapeutics has dosed the first patient with [212Pb]PSV359, a targeted alpha particle therapy for solid tumors expressing fibroblast activation protein alpha (FAP-α), a marker associated with poor prognosis in multiple cancers. - The multi-center, open-label trial will determine safety, tolerability, and preliminary anti-tumor activity of [212Pb]PSV359, with patients selected through SPECT imaging with [203Pb]PSV359 to identify FAP-α expression. - PSV359 was designed with optimized tumor uptake and retention properties, potentially offering improved therapeutic index for patients with limited treatment options across various solid tumor types.
• Perspective Therapeutics has dosed the first patient in a new cohort of its Phase 1/2a trial evaluating VMT01 in combination with Bristol Myers Squibb's nivolumab (Opdivo) for melanoma patients with positive MC1R imaging scans. • Initial results from earlier monotherapy cohorts presented at the Society for Melanoma Research showed a promising safety profile with no dose-limiting toxicities and early signs of anti-tumor activity in heavily pretreated patients. • Researchers believe VMT01's dual mechanism of action as a targeted alpha-particle therapy may enhance outcomes when combined with immune checkpoint inhibitors for patients with advanced melanoma.
- Perspective Therapeutics reported encouraging interim results from its Phase 1/2a trial of \[212Pb\]VMT-α-NET in patients with advanced neuroendocrine tumors. - The trial showed no dose-limiting toxicities or serious adverse events, with hematologic adverse events being mostly grades 1 and 2. - Further anti-tumor activity was observed with longer follow-up, including one confirmed and two unconfirmed objective responses. - The confirmed responder has remained in the study for 17 weeks, with five patients showing stable disease, suggesting potential for this radiopharmaceutical therapy.
- Perspective Therapeutics is moving forward with dose escalation of [212Pb]VMT-α-NET, a targeted alpha-particle therapy, following positive safety data in a Phase 1/2a trial. - Initial results showed durable disease control in eight of nine patients, with six experiencing measurable tumor volume reduction. - The therapy targets somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) and has received FDA Fast Track Designation. - The company plans to consult with the FDA to proceed with dose escalation based on the Safety Monitoring Committee's recommendations.
- The FDA has granted Fast Track designation to VMT01, a targeted alpha-particle therapy, for unresectable or metastatic melanoma expressing melanocortin 1 receptor (MC1R). - VMT01, developed by Perspective Therapeutics, delivers the alpha-emitting isotope 212Pb to tumor sites with MC1R overexpression, offering a novel approach to treatment. - A Phase 1/2a study (NCT05655312) is currently evaluating VMT01, with plans to explore a VMT01/anti-PD-1 combination cohort pending IRB approval. - The Fast Track designation aims to expedite VMT01's development and review, potentially offering accelerated approval and priority review for this therapy.
